- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07578038
Interest of Urinary Measurement of Immunogenic Gluten Peptides (GIP) in the Follow-up of Pediatric Celiac Patients. (GIped)
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Aline JOULIE, PHD
- Telefonnummer: +33.4.92.03.05.20
- E-post: joulie.a@chu-nice.fr
Studera Kontakt Backup
- Namn: Valérie Dr Triolo, MD
- E-post: valerie.triolo@hpu.lenval.com
Studieorter
-
-
-
Nice, Frankrike, 06200
- Fondation Lenval Hôpitaux pédiatrique Nice CHU Lenval
-
Kontakt:
- Valerie Dr Triolo, MD
- Telefonnummer: +33492030520
- E-post: valerie.triolo@hpu.lenval.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Children aged 2 to 18 years.
- Confirmed diagnosis of celiac disease according to ESPGHAN criteria.
- Gluten-free diet followed for ≥ 6 months.
- Signed informed consent by one of the 2 parents or the legal guardian and oral or written assent from the child.
- Affiliation to a social security scheme
Exclusion Criteria:
- Predictable compliance problem in the study
- Non-French-speaking patient
- Seronegative celiac disease at diagnosis
- Chronic kidney disease
- Patient protected by law, that is, subject to protective measures (judicial safeguard, guardianship, trusteeship, procedures for opening guardianship and trusteeship measures)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: GIP Group
The test used is the iVYCHECK GIP urine® test, a rapid immunochromatographic test used to detect immunogenic gluten peptides (GIP) in urine.
In the experimental group, urinary GIP levels are measured at M0, M6, and M12 with two urine samples collected at home at M6 and two urine samples collected at home at M12 in addition to the sample collected during the consultation.
|
The test used is the iVYCHECK GIP urine® test, a rapid immunochromatographic test used to detect immunogenic gluten peptides (GIP) in urine.
In the experimental group, urinary GIP levels are measured at M0, M6, and M12 with two urine samples collected at home at M6 and two urine samples collected at home at M12 in addition to the sample collected during the consultation.
Andra namn:
|
|
Aktiv komparator: control group
The test used is the iVYCHECK GIP urine® test, a rapid immunochromatographic test used to detect immunogenic gluten peptides (GIP) in urine.
In the control group, standard follow-up at M0, M6.
At M12, two urine samples collected at home in addition to the sample collected during the consultation.
|
The test used is the iVYCHECK GIP urine® test, a rapid immunochromatographic test used to detect immunogenic gluten peptides (GIP) in urine.
In the control group, standard follow-up at M0, M6.
At M12, two urine samples collected at home in addition to the sample collected during the consultation.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Compare the 1-year effectiveness of a clinical follow-up strategy based on urinary GIP measurement versus standard care, in patients with celiac disease in the pediatric population.
Tidsram: 12 month
|
The effectiveness of care guided by urinary GIP testing, combined with reinforced dietary assessment by a dietitian, will be evaluated at Month 12 using urinary GIP measurements. A positive GIP result is defined as evidence of recent gluten ingestion. The test provides an immediate binary outcome (positive or negative). At each assessment time point, patients will be classified as GIP-positive if at least one of the three urine tests performed is positive. At baseline (M0), where only a single test is conducted, GIP status will be determined based on that result alone. |
12 month
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Correlation between urinary GIP concentration and presence of gastrointestinal symptoms
Tidsram: Month 0 (baseline), Month 6, and Month 12 in the experimental group; Month 12 in the control group.
|
Assessment of the correlation between urinary glucose-dependent insulinotropic peptide (GIP) results, measured using the iVYCHECK GIP Urine Test (reported as positive or negative), and the presence of gastrointestinal symptoms.
Symptoms are defined as the presence of at least one of the following: abdominal pain, diarrhea, constipation, abdominal distension, or weight loss.
Symptom presence will be recorded as a binary outcome (yes/no).
|
Month 0 (baseline), Month 6, and Month 12 in the experimental group; Month 12 in the control group.
|
|
Correlation between urinary GIP test results and pediatrician assessment of gluten intake
Tidsram: Month 0 (baseline), Month 6, and Month 12 in the experimental group; Month 12 in the control group.
|
Assessment of the correlation between urinary glucose-dependent insulinotropic peptide (GIP) results, measured using the iVYCHECK GIP Urine Test (reported as positive or negative), and the assessment of gluten intake performed by a pediatrician. Gluten intake will be evaluated using a standardized clinical assessment based on parental interview and dietary review, and recorded as a binary outcome (gluten intake: yes/no). This assessment includes: voluntary consumption of gluten-containing foods, verification of product labels for gluten content, and evaluation of food choices during meals outside the home. |
Month 0 (baseline), Month 6, and Month 12 in the experimental group; Month 12 in the control group.
|
|
Correlation between urinary GIP test results and anti-transglutaminase antibody serology
Tidsram: Month 0 (baseline), Month 6, and Month 12 in the experimental group; Month 12 in the control group.
|
Assessment of the correlation between urinary glucose-dependent insulinotropic peptide (GIP) results, measured using the iVYCHECK GIP Urine Test (reported as positive or negative), and anti-transglutaminase antibody levels measured in serum using an enzyme-linked immunosorbent assay (ELISA), expressed in international units per milliliter (IU/mL). Serology results will be analyzed both as a continuous variable (IU/mL) and as a categorical variable defined as negative (< 7 IU/mL) or positive (≥ 7 IU/mL), according to standard laboratory thresholds. Serological assessments will be performed according to routine clinical care at Month 0 (baseline), Month 6, and/or Month 12, as prescribed by the treating physician, in both the experimental and control groups. |
Month 0 (baseline), Month 6, and Month 12 in the experimental group; Month 12 in the control group.
|
|
Assess the satisfaction of patients and parents regarding the integration of the GIP into the therapeutic follow-up strategy for adherence to the RSG
Tidsram: Month 12
|
Parental/child satisfaction will be assessed using a Likert scale responding to the following question: 'Does urinary GIP measurement during follow-up reassure you about proper adherence to the gluten-free diet?'
This question will be asked to patients over 13 years old or to parents if the child is under 13 years old, with 5 possible response levels, from strongly agree to strongly disagree.
|
Month 12
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Valérie Dr Triolo, MD, Fondation Lenval Hôpitaux pédiatrique Nice CHU Lenval
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 25-HPNCL-11 GIped
- 2026-A00599-42 (Annan identifierare: Id-RCB)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .